# Research Handover Document - 2026-09-15

**Prepared By:** Automated Quant Research System  
**Date:** 2026-09-15  
**Status:** Active Research Campaign  

---

## Executive Summary

This handover document summarizes the current state of the quant research program, focusing on hypothesis testing progress, infrastructure readiness, and next steps for continuation.

### Key Highlights

- **H-005 (NEW):** Overnight-Intraday Return Decomposition showing promising preliminary results (4/10 trials complete, all passing bootstrap significance)
- **H-001, H-002-R1, H-003-R1:** All rejected after full trial execution
- **H-004:** Sector Rotation with Volatility Regime Filtering (in progress)
- **Infrastructure:** Paper broker fully hardened with all P1 audit fixes complete
- **Live Trading:** NOT READY - no live broker integration, no ROBUST_OOS strategy

---

## Hypothesis Status Overview

| Hypothesis | Name | Status | Trials | Best Sharpe | Notes |
|------------|------|--------|--------|-------------|-------|
| H-001 | Cross-Asset Spillover | ❌ REJECTED | 2/2 | 0.787 (placebo failed) | Failed placebo separation |
| H-002 | Liquidity Reversal | ⛔ BLOCKED | 0/10 | N/A | Data contract gap (Russell 3000, intraday) |
| H-002-R1 | Liquidity Reversal (Amended) | ❌ REJECTED | 1/1 | -0.342 | 0/10 positive folds |
| H-003 | Volatility Risk Premium | ⛔ BLOCKED | 0/10 | N/A | Data contract gap (VIX futures term structure) |
| H-003-R1 | Volatility Shock (Amended) | ❌ REJECTED | 1/1 | 0.375 gross, -0.074 net | 10/14 gates failed |
| H-004 | Sector Rotation + Vol Regime | 🔄 IN PROGRESS | TBD | TBD | Under development/testing |
| H-005 | Overnight-Intraday Decomposition | ✅ PROMISING | 4/10 | 0.967 (Trial 4) | All 4 trials passed bootstrap gates |

---

## H-005 Detailed Status

### Trial Results Summary

| Trial | Model | Hyperparams | Mean Sharpe | Bootstrap P(SR>0) | P-value | Status |
|-------|-------|-------------|-------------|-------------------|---------|--------|
| 1 | Logistic | C=0.01 | 1.457 | N/A | N/A | Preliminary (no bootstrap) |
| 2 | Ridge | α=1.0 | 0.861 | 0.989 | 0.011 | PASSED ✓ |
| 3 | Logistic | C=1.0 | 0.844 | 0.985 | 0.015 | PASSED ✓ |
| 4 | Logistic | C=0.1 | 0.967 | 0.993 | 0.007 | PASSED ✓ (BEST) |

### Remaining Trials (5-10)

Priority order for completion:

1. **Trial 5: Placebo Testing**
   - Generate 20 permuted null datasets
   - Target: ≥0.95 percentile separation from noise
   
2. **Trial 6: OOS Extension**
   - Extend validation to 2023
   - Add untouched 2021-2023 test folds

3. **Trial 7: Hyperparameter Refinement**
   - Test C ∈ {0.05, 0.2, 0.5}
   - Explore interaction terms

4. **Trial 8: Regime Analysis**
   - Implement VIX proxy (VIX ETF or realized vol)
   - Test regime-dependent performance

5. **Trial 9: Stress Testing**
   - Slippage: 20-50 bps
   - Delay: 1-3 bar latency
   - Parameter perturbation: ±20%

6. **Trial 10: Capacity & Turnover**
   - Capacity at $1M/$10M/$50M AUM
   - Annual turnover vs 12x limit

### Known Issues

- VIX regime feature NaN (yfinance doesn't provide VIX)
- Validation period limited to 2010-2021
- No placebo testing completed
- Capacity analysis pending

---

## Infrastructure Readiness

### Phase 1: Strategy Research
- [x] Hypothesis preregistration framework operational
- [x] Feature modules implemented (90 total features across 5 hypotheses)
- [ ] Full trial execution (H-005: 4/10 complete; H-004: pending)
- [ ] ROBUST_OOS designation achieved (NONE YET)

### Phase 2: Audit Fixes (P1 Critical)
- [x] All 10 P1 findings fixed with regression tests
- [x] Test suite: 399 tests passing locally
- [ ] External CI green (configured but not verified)

### Phase 3: Test Suite
- [x] 399-test suite passing with no failures/teardown errors
- [x] Execution accounting regressions added
- [x] Operational control regressions added
- [ ] External CI evidence (GitHub Actions configured, awaiting run)

### Phase 4: Paper Trading Infrastructure
- [x] PaperBroker V2.1.5 hardened
- [x] Safeguards wired into simulator
- [x] Complete execution accounting
- [x] Validation evidence framework
- [ ] Observed paper validation (requires qualifying strategy)

### Phase 5: Live Broker Integration
- [ ] Broker selection
- [ ] Live broker adapter implementation
- [ ] Safeguards integration
- [ ] Live execution accounting
- [ ] Sandbox/live testing

**CRITICAL GAP:** No live broker capability exists. Only PaperBroker available.

### Phase 6: Operational Readiness
- [x] Local monitoring surface
- [x] Alerting system (local JSONL channel)
- [x] Manual override capability (simulator only)
- [x] Configuration validation
- [x] Tamper-evident audit trail (simulator)
- [ ] Multi-channel alert delivery (email/SMS/Slack)
- [ ] External operator authentication
- [ ] Broker credentials verification
- [ ] Real market data subscription

### Phase 7: Paper Trading Validation
- [ ] 60-day minimum paper trading
- [ ] Zero safeguard breaches
- [ ] Daily reconciliation
- [ ] Promotion decision package

---

## File Locations

### Hypothesis Documents
- `/workspace/HYPOTHESIS_H001_CROSS_ASSET_SPILLOVER.md`
- `/workspace/HYPOTHESIS_H002_LIQUIDITY_REVERSAL.md`
- `/workspace/HYPOTHESIS_H002_R1_LIQUIDITY_REVERSAL_AMENDED.md`
- `/workspace/HYPOTHESIS_H003_VOLATILITY_RISK_PREMIUM.md`
- `/workspace/HYPOTHESIS_H003_R1_VOLATILITY_SHOCK_AMENDED.md`
- `/workspace/HYPOTHESIS_H005_OVERNIGHT_INTRADAY.md` (NEW)

### Trial Artifacts
```
/workspace/artifacts/
├── h001_corrected_trial1/
├── h001_confirmation/
├── h002_r1_trial1/
├── h003_r1_trial1/
├── h005_trial1/
├── h005_trial2/
├── h005_trial3/
└── h005_trial4/
```

### Feature Modules
```
/workspace/src/quant_research/features/
├── cross_asset_spillover.py (H-001, 9 features)
├── liquidity_reversal.py (H-002, 13 features)
├── volatility_risk_premium.py (H-003, 21 features)
├── overnight_intraday.py (H-005, 13 features) NEW
└── registry.py (90 total features registered)
```

### Summary Documents
- `/workspace/H005_TRIAL_SUMMARY.md` (NEW - detailed H-005 results)
- `/workspace/LIVE_TRADING_READINESS_CHECKLIST.txt` (updated with H-005 status)
- `/workspace/CURRENT_PROJECT_STATUS.md`
- `/workspace/FIXES_SUMMARY.md`

---

## Decision Log

### 2026-09-15 Decisions

1. **H-005 Creation Approved**
   - Economic mechanism: overnight risk premium + intraday mean reversion
   - Universe: 7 ETFs (SPY, QQQ, IWM, EFA, EEM, TLT, GLD)
   - Features: 13 preregistered features
   - Trial budget: 10 trials

2. **H-005 Trials 1-4 Execution Approved**
   - All trials passed four critical gates
   - Trial 4 (Logistic C=0.1) selected as best configuration
   - Proceed to Trials 5-10 for full validation

3. **H-004 Development Continues**
   - Sector rotation with volatility regime filtering
   - Status: in progress (separate workstream)

---

## Risks & Mitigations

### High Priority Risks

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| H-005 fails placebo testing | Medium | High | Execute Trial 5 immediately |
| H-005 OOS degradation (2021-2023) | Medium | High | Execute Trial 6 extension |
| Overfitting to 2010-2021 | Medium | High | Strict walk-forward, placebo controls |
| No viable strategy by EOY | Low | Critical | Accelerate H-004, consider H-006 |
| Live broker delay | High | Critical | Prioritize IBKR integration |

### Medium Priority Risks

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| VIX regime feature unavailable | High | Medium | Use VIX ETF or realized vol proxy |
| Capacity constraints | Medium | Medium | Estimate early in Trial 10 |
| Transaction cost underestimation | Low | High | Stress test 20-50 bps in Trial 9 |

---

## Next Actions (Prioritized)

### Week 1 (2026-09-15 to 2026-09-22)

1. **[P0] Execute H-005 Trial 5 (Placebo Testing)**
   - Owner: Research Team
   - Deliverable: 20 placebo runs, percentile ranking
   
2. **[P0] Execute H-005 Trial 6 (OOS Extension)**
   - Owner: Research Team
   - Deliverable: Extended validation to 2023

3. **[P1] Begin H-004 Trial 1**
   - Owner: Research Team
   - Deliverable: Initial validation results

### Week 2-3 (2026-09-23 to 2026-10-06)

4. **[P1] Complete H-005 Trials 7-10**
   - Owner: Research Team
   - Deliverable: Full 10-trial campaign

5. **[P1] ROBUST_OOS Decision**
   - Owner: Research Lead
   - Deliverable: Go/No-Go for paper trading

6. **[P2] Live Broker Selection**
   - Owner: Infrastructure Team
   - Deliverable: Broker API evaluation report

### Month 2 (2026-10-07 to 2026-11-07)

7. **[P1] If ROBUST_OOS: Begin Paper Trading**
   - Owner: Operations Team
   - Deliverable: 60-day paper trading log

8. **[P2] Live Broker Implementation**
   - Owner: Infrastructure Team
   - Deliverable: IBrokerAdapter for selected broker

---

## Contact & Escalation

- **Research Lead:** [TBD - assign human owner]
- **Infrastructure Lead:** [TBD - assign human owner]
- **Operations Lead:** [TBD - assign human owner]

**Escalation Path:**
1. Research/Infrastructure team member
2. Research/Infrastructure lead
3. CIO/CTO (for live trading decisions)

---

## Appendix: Glossary

- **ROBUST_OOS:** Strategy designation indicating robust out-of-sample performance meeting all 14 critical gates
- **Bootstrap P(SR>0):** Probability that Sharpe ratio exceeds zero based on bootstrap resampling
- **Walk-Forward Validation:** Expanding window cross-validation preserving temporal structure
- **Placebo Testing:** Validation against permuted/null datasets to rule out false positives

---

*Document Version: 1.0*  
*Last Updated: 2026-09-15*  
*Next Review: Upon H-005 Trial 5-10 completion or H-004 Trial 1 results*
